The Liquid Biopsy in the Management of Colorectal Cancer: An Overview.

Abstract

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high specificity and sensitivity in patients with colorectal cancer. A "liquid biopsy" is characterized by the isolation of cancer-derived components, such as circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs, and proteins, from peripheral blood or other body fluids and their genomic or proteomic assessment. The liquid biopsy is a minimally invasive and repeatable technique that could play a significant role in screening and diagnosis, and predict relapse and metastasis, as well as monitoring minimal residual disease and chemotherapy resistance in colorectal cancer patients. However, there are still some practical issues that need to be addressed before liquid biopsy can be widely used in clinical practice. Potential challenges may include low amounts of circulating tumor cells and circulating tumor DNA in samples, lack of pre-analytical and analytical consensus, clinical validation, and regulatory endorsement. The aim of this review was to summarize the current knowledge of the role of liquid biopsy in the management of colorectal cancer.

• Authors: Marco Vacante, Roberto Ciuni, Francesco Basile, Antonio Biondi
• Journal: Biomedicines (Biomedicines) Vol. 8 Issue 9 (Aug 26 2020) ISSN: 2227-9059 [Print] Switzerland
• PMID: 32858879 (Publication Type: Journal Article, Review)